Batavia Biosciences has expanded its viral vector process development facilities in the U.S. and its GMP clean room facilities in the Netherlands.
 
Enhanced capabilities at the company’s R&D facility in Medford, MA allows Batavia to extend its existing service portfolio in the U.S., adding complete preclinical process development capabilities for viral vectors including AAV, Lentivirus, VSV and Adenovirus systems to its portfolio of CHO cell line generation and process development services for recombinant proteins and antibodies.

Expansion of its GMP clean room facilities in Leiden, the Netherlands expands the company’s GMP capacity with increased R&D capability to further support the manufacture of master cell banks and vaccine seed stocks.
 
Chris Yallop, chief scientific officer, Batavia Biosciences, said, “Recent advances in cancer vaccines and gene therapy have given rise to a profound increase in the global demand for process development and clinical manufacturing of vector based products.”
 
Menzo Havenga, chief executive officer, Batavia Biosciences, added, “At Batavia Biosciences we are very much aware of the fact that the patient is waiting. With the completion of this investment, the company is now better positioned to maintain the speed and quality of bringing candidate biopharmaceuticals from bench to clinic.”